Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28595983 | 0.83 | EPAS1 (0.39) | EPAS1PKMNR3C1MAPK14CARM1 | |
| SCHEMBL21652832 | 0.76 | PKM (0.47) | EPAS1PKMHSPB1KDM4E | |
| SCHEMBL29915547 | 0.76 | PKM (0.47) | EPAS1PKMHSPB1KDM4E | |
| SCHEMBL21633979 | 0.73 | EPAS1 (0.43) | EPAS1PKMMAPK14CARM1MAPT | |
| SCHEMBL23403939 | 0.73 | PKM (0.44) | EPAS1PKMHSPB1MAPK14GCK | |
| SCHEMBL21652833 | 0.73 | EPAS1 (0.47) | EPAS1HSPB1MAPK14TRPA1 | |
| SCHEMBL21652766 | 0.72 | EPAS1 (0.41) | EPAS1PKMMAPK14GCKMAPT | |
| SCHEMBL30957817 | 0.72 | EPAS1 (0.41) | EPAS1PKMMAPK14GCKMAPT | |
| SCHEMBL30957814 | 0.72 | EPAS1 (0.41) | EPAS1PKMMAPK14GCKMAPT | |
| SCHEMBL21634034 | 0.70 | EPAS1 (0.47) | EPAS1HSPB1MAPK14TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716827-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-112424200-B | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| CN-112424200-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | BRD1, BRD4, BRD2 | EPAS1 3006/4885PKM 2881/4885NR3C1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.